Journal Guide

By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new digital academic era. .

Aims and Scope: ALTEX, edited by the Swiss Society ALTEX Edition is the official journal of CAAT (Center for Alternatives to Animal Testing, Johns Hopkins University, Baltimore, USA), EUSAAT (European Society for Alternatives to Animal testing) and T4 (transatlantic think tank of toxicology, Baltimore, Konstanz, Utrecht). ALTEX, issued by the Swiss society ALTEX Edition, is the official journal of ASCCT, the American Society for Cellular and Computational Toxicology, CAAT, the Center for Alternatives to Animal Testing at the Johns Hopkins University Baltimore, USA, CAAT-Europe the Center for Alternatives to Animal Testing Europe at the University of Konstanz, Germany, EUSAAT, the European Society for Alternatives to Animal Testing, t4, the transatlantic think tank of toxicology (Baltimore, Utrecht, Konstanz) and the Doerenkamp chairs in Germany, India, The Netherlands, Switzerland and USA. ALTEX publishes original articles, short communications, reviews, as well as news and comments, meeting reports and book reviews. ALTEX is devoted to the publication of research on the development and promotion of alternatives to animal experiments according to the 3R concept of Russell and Burch: Replace, Reduce, and Refine. Animal experiments are defined as all experimental procedures involving the use of animals in testing, research and education or to obtain tissues, organs, and other animal-derived products which may cause pain or distress to animals. ALTEX further publishes manuscripts on the bioethics of the complex relationship between humans and animals. Articles published in ALTEX must express a basic concern for the dignity of living creatures and the recognition of animals as our partners. All articles are judged according to stringent scientific standards. Manuscripts submitted to , ALTEX are evaluated by two reviewers. The evaluation takes into account the scientific merit of a manuscript and its contribution to animal welfare and the 3R principle. Please visit www.altex-edition.org for further information. Copyright: Society ALTEX Edition, Kuesnacht, Zurich

Alzheimer Disease and Associated Disorders is a leading international forum for reports of new research findings and new approaches to diagnosis and treatment. Contributions fall within all relevant scientific fields and clinical specialties, including neurobiology, neurochemistry, molecular biology, neurology, neuropathology, neuropsychology, psychiatry, gerontology, and geriatrics. Rigorous peer review of articles is ensured by an international Editorial Advisory Board of eminent scientists and clinicians. Website: www.alzheimerjournal.com.

The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.

Given the growing number of specialized manuscripts in the field of Alzheimer's and dementia research, DADM will provide an expanded platform to provide a) rapid communication and publication that facilitate cross-fertilization of ideas, b) integrating and translating knowledge across disciplines; disseminating basic and clinical information necessary for optimal translation of research into practical applications and interventions, c) increase knowledge in diverse areas of studies with potentials/implications for practical application related to early detection and/or interventions, d) formulating crucial experiments necessary for the rigorous testing of theories or their predictions, and e) identifying promising new directions of research and providing the impetus or the scientific foundation for new initiatives on interventions.

The mission of Alzheimer's & Dementia: Journal of the Alzheimer's Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services. The journal publishes • comprehensive reviews; • research articles; • information on clinical trials; • short reports;• in-depth perspectives/open-peer commentaries; • theoretical and/or translational papers that attempt integrate knowledge across discipline;• history & politics of science/brief biographies and, • abstracts of papers presented at international meetings. Negative results, particularly clinical trials, are published as short communications.The ultimate objective is to create a novel forum for: • rapid communication of new findings, ideas or perspectives; • disseminating knowledge, across the spectrum of basic to clinical studies, necessary for optimal translation of research findings into practical applications/interventions; • integrating knowledge across disciplines; • increase knowledge in diverse disciplines to promote early detection/diagnosis and/or interventions; • formulating new theories and/or strategies for the rigorous testing of theories or their predictions; • identifying promising new directions of research and, • providing the scientific impetus for new initiatives; or public policies concerning research on prevention and new models of health services.Alzheimer's & Dementia is indexed/abstracted in Index Medicus/MEDLINE, Scopus, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Neuroscience Citation Index®, and Journal Citation Reports/Science Edition.

Alzheimer's & Dementia: Translational Research & Clinical Interventions (TRCI) is an open access, peer-reviewed, journal from the Alzheimer's Association® that covers translational research and clinical therapeutics for Alzheimer's disease, dementia and other age-related conditions affecting cognition, memory, and behavior. The journal will provide a rapid method for communication among a multidisciplinary clinical research audience involving the range of therapeutic interventions (e.g., drugs, biologicals, devices, and psychotherapeutic, psychosocial, and non-pharmacological modalities) from preclinical development to late stage trials and health technology assessment.

The focus is original, feature length research articles, systematic reviews, metaanalyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that advance the prevention and treatment of Alzheimer's disease, dementia, and cognitive impairment. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurology, psychiatry, clinical psychology, bioinformatics, and health policy as they apply to preclinical and clinical therapeutics. It will focus on discovery, therapeutic development, clinical pharmacology, preclinical studies, and the application of neuropsychology, clinical ratings, clinical trials methods, neuroimaging, biomarkers, clinical research informatics, and other interdisciplinary approaches to clinical therapeutics and outcomes.

Given the growing number of specialized manuscripts in the field of Alzheimer's and dementia research, TRCI provides an expanded platform for the publication of clinical translational research. TRCI encourages the submission of manuscripts that describe preclinical research with a potential for clinical application, research from early human experimentation (experimental medicine) that may advance clinical treatment and prevention of Alzheimer pathology, neurodegeneration, and cognitive impairment.

Like Alzheimer's & Dementia, TRCI will publish manuscripts describing public health research with the potential for application for disease prevention or clinical therapeutics that bridges the laboratory and clinical settings, and laboratory studies of novel therapeutic interventions and new treatment paradigms. Expanding on the growing number of submissions to Alzheimer's & Dementia, TRCI will provide a rapid communication vehicle for manuscripts that focus on translation and clinical research methods, procedures, protocols, analytical approaches and regulatory science.